Equity research analysts tracking Puma Biotechnology maintain 12-month consensus price targets that fluctuate based on quarterly prescription sales volumes and oncology portfolio updates. Median institutional estimates generally suggest moderate upside potential from current small-cap valuations, though exact targets shift dynamically with each corporate earnings release and commercial performance metric.